Enterovirus 68

Enterovirus 68 (EV-D68) is a member of the Enterovirus genus, which is part of the Picornaviridae family. It is a non-polio enterovirus that can cause mild to severe respiratory illness. EV-D68 was first identified in California in 1962 and has since been associated with various outbreaks worldwide.
Virology[edit]
EV-D68 is a single-stranded, positive-sense RNA virus. It shares many characteristics with other enteroviruses but is unique in its preference for the respiratory tract. The virus is primarily transmitted through respiratory secretions, such as saliva, nasal mucus, or sputum.
Symptoms[edit]
The symptoms of EV-D68 infection can range from mild to severe and include:
In severe cases, EV-D68 can lead to acute flaccid myelitis (AFM), a rare but serious condition that affects the spinal cord and can cause muscle weakness and paralysis.
Diagnosis[edit]
Diagnosis of EV-D68 infection is typically made through laboratory testing of respiratory specimens. Polymerase chain reaction (PCR) is commonly used to detect the presence of the virus's RNA.
Treatment[edit]
There is no specific antiviral treatment for EV-D68. Management of the infection primarily involves supportive care, such as:
- Hydration
- Oxygen therapy
- Mechanical ventilation in severe cases
Prevention[edit]
Preventive measures to reduce the risk of EV-D68 infection include:
- Frequent handwashing with soap and water
- Avoiding close contact with infected individuals
- Disinfecting frequently touched surfaces
- Covering coughs and sneezes with a tissue or elbow
Epidemiology[edit]
EV-D68 has been associated with several outbreaks, particularly in the United States. Notable outbreaks occurred in 2014 and 2018, leading to increased awareness and surveillance of the virus.
See also[edit]
References[edit]
External links[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian